Akeso up 11%, hitting a more than one-month high.

As of press time, Akeso rose 11% to a more than one-month high, with turnover of HK$1.1 billion. Recently, Akeso's globally first-in-class tumor immunology 2.0 cornerstone drug ivonescimab presented the latest overall survival data from the HARMONi-2 study at the 2026 World Conference on Lung Cancer. According to Akeso, compared with Merck & Co.'s pembrolizumab, ivonescimab significantly extended median overall survival to 30.8 months, while pembrolizumab's median overall survival was 22.6 months.